Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells.
We studied the effect of retinoic acid on the growth and secretory activity of the androgen-responsive prostatic carcinoma cell line LNCaP. Our data showed that retinoic acid at 0.01 microM. stimulated the proliferation of LNCaP cells but inhibited their growth at 0.1 microM. under androgen-free conditions. In the presence of 0.1 nM. dihydrotestosterone (DHT), LNCaP cell proliferation was inhibited by 10 microM. retinoic acid but not by lower concentrations of retinoic acid. Retinoic acid reduced LNCaP cell growth at concentrations of 0.1 microM. in the presence of 10 nM. DHT. Retinoic acid (10 microM.) also reduced the growth response of LNCaP cells to epidermal growth factor and transforming growth factor alpha and potentiated the inhibitory effect of transforming growth factor beta. In additional studies, retinoic acid induced a dose-dependent increase in prostate specific antigen (PSA) secretion at concentrations of 0.1 to 1 microM. Dihydrotestosterone (10 nM.) also enhanced the secretion of PSA by LNCaP cells, and this effect was potentiated in a dose-dependent fashion by the addition of retinoic acid at 0.1-10 microM. Competitive binding studies showed that retinoic acid did not bind to androgen receptors. Overall, retinoic acid had a biphasic effect on LNCaP proliferation and promoted the secretion of PSA. The biphasic effect of retinoic acid on LNCaP growth should be considered in designing in vivo studies to determine the impact of retinoic acid on solid prostatic tumor growth. In addition, the ability of retinoic acid to increase PSA secretion may complicate the interpretation of serum PSA levels used for diagnostic and prognostic purposes.
Fong
C J
CJ
Department of Urology, Northwestern University Medical School, Chicago, Illinois 60611.
Sutkowski
D M
DM
Braun
E J
EJ
Bauer
K D
KD
Sherwood
E R
ER
Lee
C
C
Kozlowski
J M
JM
D000728:Androgens / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D013196:Dihydrotestosterone / Q000378:metabolism; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D015741:Metribolone / Q000378:metabolism; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology*; D011944:Receptors, Androgen / Q000378:metabolism; D013739:Testosterone / Q000378:metabolism; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000378:metabolism
D000728:Androgens; D011944:Receptors, Androgen; D013196:Dihydrotestosterone; D015741:Metribolone; D013739:Testosterone; D014212:Tretinoin; D017430:Prostate-Specific Antigen